Skip to main content
Advertising

Originally published January 13, 2014 at 4:25 PM | Page modified January 13, 2014 at 9:14 PM

  • Share:
           
  • Comments (0)
  • Print

Juno Therapeutics bumps startup funding to $145M

Amazon founder Jeff Bezos and others have added at least $25 million to the already hefty initial funding of Juno Therapeutics, the Seattle biotechnology startup unveiled last month by leading cancer scientists here and in New York.


By Seattle Times business staff

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

Juno Therapeutics, the Seattle biotechnology startup unveiled last month by leading cancer scientists here and in New York, has bumped its initial financing round to more than $145 million with new backing from Amazon.com founder Jeff Bezos and others.

The immunotherapy company on Monday said it has tacked about $25 million more onto last month’s already record-breaking $120 million start-up financing. The added investors include Bezos Expeditions, the Amazon chairman’s personal investment fund, and the venture capital firm Venrock.

Juno CEO Hans Bishop said in a recent interview that the company’s approach to bolstering patients’ cancer-fighting immune responses has attracted such big money because “the science is extraordinary and the potential is extraordinary.” But he cautioned, “There’s still a lot of work to do.”

Juno was formed in partnership with Fred Hutchinson Cancer Research Center, New York’s Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute.



News where, when and how you want it

Email Icon

Subscribe today!

Subscribe today!

Get 8 weeks of digital access to The Seattle Times for $1

Advertising

Advertising


Advertising
The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►